Company intelligence / Profile preview

CorMedix Inc.

Berkeley Heights, New Jersey, United Statescormedix.com ↗

Ownership: Public · CRMD
Employees: ~65
Development stage: Commercial

Overview

DefenCath (taurolidine and heparin) received FDA approval on November 15, 2023, and was commercially launched in inpatient settings in April 2024 and outpatient settings in July 2024. The product reduces catheter-related bloodstream infection risk by 71% for dialysis patients[2][3].

Therapeutic areas: Infectious DiseasesNephrology
Modalities: Antimicrobial solutionsmedical devices
Industry: Biotech

Drug pipeline

6 assets

taurolidine

5 more assets in the full pipeline.

Partnerships

ARC Dialysis, LLC (commercial agreement announced August 4, 2024)[9]

Financials

Market cap: $407.6M
Total revenue: $311.7M
Enterprise value: $296.1M

Beyond the preview

Go deeper on CorMedix Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CorMedix Inc..